Anti Phospholipid
Mostrando 1-12 de 88 artigos, teses e dissertações.
-
1. Anti-phospholipid syndrome in seven leprosy patients with thrombotic events on corticosteroid and/or thalidomide regimen: insights on genetic and laboratory profiles
Abstract INTRODUCTION Corticosteroids and/or thalidomides have been associated with thromboembolism events (TBE) in multibacillary (MB) leprosy. This report aimed to determine genetic and laboratory profiles associated with leprosy and TBE. METHODS Antiphospholipid antibodies (aPL), coagulation-related exams, prothrombin and Leiden’s factor V mutations
Rev. Soc. Bras. Med. Trop.. Publicado em: 2018-02
-
2. Lepromatous leprosy patients produce antibodies that recognise non-bilayer lipid arrangements containing mycolic acids
Non-bilayer phospholipid arrangements are three-dimensional structures that form when anionic phospholipids with an intermediate structure of the tubular hexagonal phase II are present in a bilayer of lipids. Antibodies that recognise these arrangements have been described in patients with antiphospholipid syndrome and/or systemic lupus erythematosus and in
Mem. Inst. Oswaldo Cruz. Publicado em: 2012-12
-
3. INFLUÊNCIA DO ÔMEGA 3 SOBRE SINTOMAS EXTRAPIRAMIDAIS, DEFICIÊNCIA COGNITIVA E PARÂMETROS DE ESTRESSE OXIDATIVO EM ANIMAIS TRATADOS COM NEUROLÉPTICOS
Haloperidol and fluphenazine are typical neuroleptics widely used in the treatment of mental illness, whose chronic use is associated with adverse effects that affect the motor function and memory, among others. The motor disturbances can be moderate, and include parkinsonism, akathisia, dystonia, but also a more severe syndrome, known as tardive dyskinesia
Publicado em: 2009
-
4. Aterosclerose na artrite reumatóide e sua associação com auto-imunidade humoral / Atherosclerosis in rheumatoid arthritis and its relationship with humoral autoimmunity
Purpose: Many questions remain unanswered about the causes of accelerated atherosclerosis in patients with inflammatory systemic diseases such as rheumatoid arthritis (RA). Some studies have suggested the role of autoimmunity besides inflammation in the pathogenesis of atherosclerosis in general population and have also discussed the possible association wit
Publicado em: 2007
-
5. Reversão do fenótipo de resistência a múltiplas drogas em células de sarcoma uterino humano. Utilização de emulsão lipídica como veículo de oligonucleotídeos antissenso / Reversion of the multiple drug resistance phenotype in a human sarcoma cell line. Lipid emulsion as antisense oligonucleotide vector
The objective of this study was to evaluate the usefulness of a nanolipid emulsion (LDE) as a vector to carry antisense oligonucleotides (OAS). LDE is a nanoemulsion consisting of 48% cholesterol esters, 47,8% phospholipid, 2,3% triglycerides and 1,9% unesterified cholesterol. It is able to obtain apoE from HDL and interact with B/E receptor. The metabolic b
Publicado em: 2007
-
6. Estratégias para prospecção e predição de peptídeos bioativos
Chapters one and two deal with the isolation and identification of bioactive peptides from the skin secretion of Phyllomedusa hypochondrialis. The first chapter demonstrates the use of protemic techniques, mainly mass spectrometry, for the study of bradykinin related peptides (BRPs) present in the amphibians secretion and freshly dissected skin fragments. Ei
Publicado em: 2007
-
7. Metabolismo de lipoproteinas plasmaticas em tabagistas : proteinas reguladoras e modificações quimicas das lipoproteinas de baixa densidade
A aterosclerose é uma doença imuno-inflamatória e de caráter multifatorial. O tabagismo é um de seus principais fatores de risco, existindo grande controvérsia na literatura quanto aos mecanismos fisiopatológicos de sua aterogenicidade. Avaliamos os efeitos metabólicos e oxidantes do fumo em urna população sadia adulta, composta de fumantes crônic
Publicado em: 2002
-
8. Anti-Cardiolipin and Anti-Phosphatidylglycerol Antibodies Prepared Against Bacterial Phospholipids
Anti-phosphatidylglycerol and anti-cardiolipin antisera were prepared in rabbits by using phospholipids purified from Micrococcus lysodeikticus. Anti-phosphatidylglycerol antibodies were found in antisera when either phosphatidylglycerol or cardiolipin were used as immunogens, but adsorption studies indicated they were not similar. Antibodies which reacted w
-
9. Inhibition of human factor VIIIa by anti-A2 subunit antibodies.
Human inhibitory alloantibodies and autoantibodies to Factor VIII (FVIII) are usually directed toward the A2 and/or C2 domains of the FVIII molecule. Anti-C2 antibodies block the binding of FVIII to phospholipid, but the mechanism of action of anti-A2 antibodies is not known. We investigated the properties of a patient autoantibody, RC, and a monoclonal anti
-
10. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus.
The restriction of phosphatidylserine (PtdSer) to the inner surface of the plasma membrane bilayer is lost early during apoptosis. Since PtdSer is a potent surface procoagulant, and since there is an increased incidence of coagulation events in patients with systemic lupus erythematosus (SLE) who have anti-phospholipid antibodies, we addressed whether apopto
-
11. Stimulation of phospholipid methylation, Ca2+ influx, and histamine release by bridging of IgE receptors on rat mast cells.
Normal rat mast cells were stimulated by antibodies against IgE receptors (anti-RBL) or by anti-IgE, and [3H]methyl group incorporation into phospholipids, 45Ca uptake, and histamine release were examined. Anti-RBL or its F(ab')2 fragments and anti-IgE induced an increase in the incorporation of [3H]methyl into phospholipids, in 45Ca influx, and in histamine
-
12. Anticardiolipin antibodies: isotype distribution and phospholipid specificity.
Quantitative isotype specific enzyme linked immunosorbent assay (ELISA) was used to determine the distribution of immunoglobulin isotypes and phospholipid specificities of anticardiolipin (anti-CL) antibodies in 40 patients with one or more of the following 'antiphospholipid (anti-PL) antibody associated clinical complications'--namely, thrombosis, fetal los